Crown Bioscience International
Crown Bioscience International, often referred to as CrownBio, is a leading global provider of preclinical and translational research services, headquartered in Taiwan (TW). Established in 2006, the company has rapidly expanded its operational footprint across North America, Europe, and Asia, positioning itself as a key player in the biotechnology and pharmaceutical industries. CrownBio specialises in offering innovative solutions in drug discovery and development, with a focus on oncology, immunology, and metabolic diseases. Their unique suite of services includes patient-derived xenograft (PDX) models and advanced in vitro assays, which are designed to accelerate the drug development process. Recognised for its commitment to quality and scientific excellence, CrownBio has achieved significant milestones, including partnerships with major pharmaceutical companies, solidifying its reputation as a trusted partner in the life sciences sector.
DitchCarbon Score
How does Crown Bioscience International's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Crown Bioscience International's score of 45 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Crown Bioscience International, headquartered in Taiwan (TW), currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of JSR Corporation, which cascades its climate commitments and targets down to Crown Bioscience. JSR Corporation, at the first cascade level, has established various climate initiatives, including Science Based Targets (SBTi) and CDP reporting, which inform Crown Bioscience's climate strategy. However, specific reduction targets or achievements for Crown Bioscience International have not been disclosed. As part of its commitment to sustainability, Crown Bioscience aligns with the broader goals set by its parent company, JSR Corporation, to enhance environmental performance and reduce carbon footprints across its operations. The absence of direct emissions data highlights the need for further transparency and reporting in the company's climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,300,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 2 | 1,400,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - |
| Scope 3 | - | - | - | - | - | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Crown Bioscience International is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
